Cannabis Law Report

JUNE 30, 2021

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 12, 2021

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Veriheal

MAY 26, 2022

Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play. The ORR, an ongoing online survey study, collects self-reported health information to be analyzed by Johns Hopkins for published research papers. Bringing Cannabis Into Mainstream Medicine.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Veriheal

AUGUST 31, 2020

Program between St. About Sinibaldo: Sinibaldo is an aspiring healthcare professional and a biomedical researcher in the Medical Scientist Training Program (M.D./Ph.D.) About Nishtha: Nishtha is pursuing neurology to become a physician-scientist in honor of her grandmother Nani who suffered from Alzheimer’s.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JANUARY 6, 2022

Anderson will be responsible for Anebulo’s global investor relations and public relations programs. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. 1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. P1 (Brazil), and B.1.526

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing. Visit adnas.com for more information. STONY BROOK, N.Y.–(BUSINESS

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Develop and maintain the Core Data Sheet and lead global labeling team meetings. to attain group goals.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Veriheal

APRIL 11, 2022

He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials. territories. This means that U.S. The post New U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Visit adnas.com for more information. Join our mailing list.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

MAY 29, 2022

Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Conducting a Psilocybin Administration Session (20 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

AUGUST 3, 2021

The Contract specifies ADCL’s deployment of safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide weekly asymptomatic diagnostic COVID-19 screening of on-campus unvaccinated students, staff, and faculty, and a random sampling of vaccinated individuals across the CUNY school system. Join our mailing list.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

DECEMBER 7, 2021

However, despite the increased use of MCs in children, there is limited data regarding their safety and efficacy in this population for those different indications 11. A systematic review published in 2017 aimed to identify available data about the therapeutic effect of cannabinoids treatment in children and adolescents.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

NOVEMBER 15, 2021

CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. Visit adnas.com for more information. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program Manager: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN. Join our mailing list.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

TheAnswerPage

JANUARY 11, 2022

In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. In most cases, state medical marijuana legislation was passed without input from individual medical professionals or the medical community.

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). An anti-seizure wonder drug.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

JUNE 1, 2021

Drake received her bachelor’s degree from Wichita State University and is a graduate of the Harvard Business School Executive Leadership Program. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Investor Presentation Information. Additional Information and Where to Find It.

Therapy 52

Therapy Research and Development Business Access 52

Puff Puff Post

SEPTEMBER 16, 2019

Santé Cannabis, a pioneer in medical cannabis in Québéc , has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

Programs 108

Programs Research and Development Education Treatment 108

Puff Puff Post

SEPTEMBER 16, 2019

Santé Cannabis, a pioneer in medical cannabis in Québéc , has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. For further information about Anebulo, please visit www.anebulo.com. Condensed Balance Sheet Data. . .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Project CBD

MAY 3, 2023

It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research. Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children. But we may be on the cusp of having those trials, which would be very exciting. I really enjoy it.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JANUARY 9, 2019

Tindall also hope to commence the clinical trials with Vanuatu for diabetes treatment. It’s important to us to run local trials, so we are not relying on evidence from elsewhere,” Tindall said. “It It also gives us a fast-track program. It’s all about access and education,” said Tindall. “If

Therapy 85

Therapy Clinical Trials Treatment Medicine 85